DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Advanced Recurrent Ovarian Cancer Clinical Trial Pipeline Landscape

September 07 15:02 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Advanced Recurrent Ovarian Cancer Clinical Trial Pipeline Landscape

The Advanced Recurrent Ovarian Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Recurrent Ovarian Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Recurrent Ovarian Cancer pipeline landscape and fostering the potential growth of Advanced Recurrent Ovarian Cancer therapeutic advancements.

 

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

  • DelveInsight’s Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
  • The leading companies working in the Advanced Recurrent Ovarian Cancer market include IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc., Glycotope GmbH, and others.
  • Promising Advanced Recurrent Ovarian Cancer Pipeline Therapies in the various stages of development include Pembrolizumab, MEDI3617, Bevacizumab, Carboplatin, AMG 386, MM-121, DOXIL, Trabectedin, Dexamethasone, and others.
  • On January 2023, Takeda announced a study of Phase 2 Clinical Trials for Niraparib. The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4 previous chemotherapy regimens.
  • On January 2023, Precigen Inc. announced a study of Phase 1 Clincial Trials for PRGN-3005 UltraCAR-T cells. This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy.
  • On February 2023, Sumitomo Pharma Oncology Inc. announced a study of Phase 1 Clinical Trials for TP-0903. TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers. Preclinical studies have shown promising antitumor activity of TP-0903 as a single agent against a variety of tumor types in both in vitro and in vivo studies.
  • On March 2023, Bayer announced a study of Phase 1 Clinical Trials for BAY2287411. The purpose of this study is to evaluate, in patients with tumors known to express the protein mesothelin. 

 

Request a sample and discover the recent advances in Advanced Recurrent Ovarian Cancer Treatment Drugs @ Advanced Recurrent Ovarian Cancer Infection Pipeline Report

 

The Advanced Recurrent Ovarian Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Recurrent Ovarian Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Recurrent Ovarian Cancer clinical trial landscape.

 

Advanced Recurrent Ovarian Cancer Overview

Ovarian cancer refers to cancer that arises in the almond-shaped reproductive organs in women in which eggs, or ova, are produced (ovaries), in either of the two tubes through which eggs travel from the ovaries to the uterus (fallopian tubes), or in the membrane that lines the pelvis and the abdominal cavity and covers all of the abdominal organs (peritoneum).

 

Find out more about Advanced Recurrent Ovarian Cancer Treatment Drugs @ Drugs for Advanced Recurrent Ovarian Cancer Treatment

 

Advanced Recurrent Ovarian Cancer Emerging Drugs Profile

  • Maveropepimut S: IMV
  • ELU 001: Elucida Oncology
  • A166: Klus Pharma

 

Advanced Recurrent Ovarian Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Advanced Recurrent Ovarian Cancer. The Advanced Recurrent Ovarian Cancer companies which have their Advanced Recurrent Ovarian Cancer drug candidates in the most advanced stage, i.e. phase II include, IMV.

 

Learn more about the emerging Advanced Recurrent Ovarian Cancer Pipeline Therapies @ Advanced Recurrent Ovarian Cancer Clinical Trials Assessment

 

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc., Glycotope GmbH, and others.
  • Advanced Recurrent Ovarian Cancer Pipeline Therapies- Pembrolizumab, MEDI3617, Bevacizumab, Carboplatin, AMG 386, MM-121, DOXIL, Trabectedin, Dexamethasone, and others.

 

Dive deep into rich insights for new drugs for Advanced Recurrent Ovarian Cancer Treatment, Visit @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Recurrent Ovarian Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Recurrent Ovarian Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Maveropepimut S: IMV
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Recurrent Ovarian Cancer Key Companies
  21. Advanced Recurrent Ovarian Cancer Key Products
  22. Advanced Recurrent Ovarian Cancer- Unmet Needs
  23. Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
  24. Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
  25. Advanced Recurrent Ovarian Cancer Analyst Views
  26. Advanced Recurrent Ovarian Cancer Key Companies
  27. Appendix

 

For further information on the Advanced Recurrent Ovarian Cancer pipeline therapeutics, reach out to Advanced Recurrent Ovarian Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting